Back to Screener

Healthcare

Scancell Holdings plc(SCNLF)

Live Price

Offline

$0.245

-26.84% today

Window Change

-24.36%

Window

May 29, 2026 โ†’ Jun 15, 2026

Market Cap
$160.00M
Revenue Growth
-10.6%
EPS Growth
-85.3%
Dividend Yield
0.0%
Sparse coverage

Historical coverage is still filling in

This 1Y daily history view is currently sparse. Use it as directional context while we continue backfilling more history.

Coverage: 12 bars ยท May 29, 2026 โ†’ Jun 15, 2026

Research Briefing

A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.

Decision context

Research Snapshot

Scancell Holdings plc (SCNLF) is a Healthcare stock with a market cap of $160.00M and listed on OTC. The stock last traded around $0.24 and down 24.4% across the available one-year price window (May 29, 2026 โ†’ Jun 15, 2026). Baseline metrics include revenue growth of -10.6%, EPS growth of -85.3%, a dividend yield of 0.0%. What stands out right now is revenue -10.6%, EPS -85.3%, free cash flow +59.5% with operating margin -283.3% and ROIC -113.8%. Valuation already assumes a fairly strong business story at price/sales 33.3. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines SCNLF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.

Sector Context

How this name stacks up against nearby peers on first-pass metrics.

Revenue Growth

Below sector median

-10.6% vs +7.6% peer median

Operating Margin

Below sector median

-283.3% vs +19.4% peer median

What Changed This Quarter

Latest report context and the signals most likely to have changed the story.

Latest report is on the board

2026 was reported on Jan 29, 2026, but the surprise data is still limited.

The operating picture looks softer than before

Revenue is at -10.6% and EPS is at -85.3%, with operating margin around -283.3%.

The next real check-in already has a date

The next earnings event is scheduled for Oct 23, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.

Benchmark Comparison

Normalized Performance vs SPY

Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.

1Y shared range

SCNLF

โ€”

Normalized return

SPY

โ€”

S&P 500

Excess Return

โ€”

Relative to SPY

SCNLF Max Drawdown

-26.84%

Trailing 1Y

SPY Max Drawdown

โ€”

Trailing 1Y

Benchmark comparison is loading or unavailable right now.

Calendar-Year Returns

Uses the longest available daily history for SCNLF and SPY.

Calendar-year return history is still loading or unavailable.
Scancell Holdings plc logo

Company Overview

Scancell Holdings plc

Other OTC

Oxford, GB
Visit scancell.co.ukCall IR44 18 6558 2066

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, an ImmunoBody cancer vaccine for the treatment of metastatic melanoma; SCIB2/iSCIB2 vaccine, which is under evaluation for the treatment of patients with solid tumours, including non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

Leadership
Phillip John L'Huillier
IPO Date
Aug 2, 2013
Employees
61
Street Address
Bellhouse Building
Mailing
Oxford, OX4 4GD
Region
Oxford, GB
Reporting Currency
USD
Investor Line
44 18 6558 2066
Last Updated
May 4, 2026
ISIN: GB00B63D3314
Reports in USD

Key Fundamentals

Valuation, growth, profitability, and balance sheet signals.

Valuation

P/E
โ€”
EV/EBITDA
โ€”
Price/Sales
33.3
Price/Book
โ€”

Growth

Revenue
-10.6%
EPS
-85.3%
Free Cash Flow
+59.5%

Profitability

Gross Margin
78.5%
Operating Margin
-283.3%
Net Margin
-117.0%
ROE
90.3%
ROIC
-113.8%

Balance Sheet

Debt/Equity
โ€”
Current Ratio
0.56

Earnings Reports

๐Ÿ“… Next earningsOct 23, 2026
PeriodB/MEPSEPS ฮ”RevenueRev ฮ”
โ€”
Oct 23, 26
TBD
โ€”
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jan 29, 26
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 26, 25
0.00
Est โ€”
โ€”
6259.1B
Est โ€”
โ€”
โ€”
Jan 28, 25
-0.02
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Sep 24, 24
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jan 30, 24
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Apr 30, 23
-0.01
Est โ€”
โ€”
6588.4B
Est โ€”
โ€”
โ€”
Jan 25, 23
-0.00
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Oct 28, 22
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Dec 22, 21
0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Oct 29, 21
-0.02
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jan 29, 21
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Oct 16, 20
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jan 31, 20
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Aug 20, 19
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”
โ€”
Jan 31, 19
-0.01
Est โ€”
โ€”
โ€”
Est โ€”
โ€”

Latest News

No news articles available

Official Releases

Company announcements and filings-style updates.

Official
No official releases available

Next Step

Keep the research moving

After the overview, the strongest next step is usually chart context or a tighter compare set.

Explore the advanced chart guideRead how to compare stocks